Sulindac (Copal)

Subscribe to Selected New Research on Sulindac

715 relevant articles (62 outcomes, 149 trials/studies) found for this Drug

Description: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.

Also Known As:

Copal; Clinoril; Aclin; Alphapharm Brand of Sulindac; Apo-Sulin; Apotex Brand of Sulindac; Arthrobid; Arthrocine; Cahill May Roberts Brand of Sulindac; Chemia Brand of Sulindac; Chibret; Kenalin; Kendrick Brand of Sulindac; Klinoril; MK-231; Merck Brand of Sulindac; Merck Sharp & Dohme Brand of Sulindac; Novo-Sundac; Novopharm Brand of Sulindac; Nu-Pharm Brand of Sulindac; Nu-Sulindac; Sulindal; Apo Sulin; MK 231; MK231; Novo Sundac; Nu Pharm Brand of Sulindac; Nu Sulindac; 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (Z)-

Relationship Network

Drug Context: Research Results

Organic Chemicals: 42

Hydrocarbons: 362

Cyclic Hydrocarbons: 3

Aromatic Hydrocarbons: 121

Aromatic Polycyclic Hydrocarbons: 617

(5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride: 6

nitrosulindac: 3

(5-fluoro-2-methyl-1-(3,5-dimethoxy-4-hydroxybenzylidene)-3-(N-benzyl)indene)acetamide: 1

2-(1-benzylidene-5-bromo-2-methyl-1H-inden-3-yl)acetic acid

sulindac derivative IND 12

Polycyclic Compounds: 59

Aromatic Polycyclic Hydrocarbons: 617

(5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride: 6

nitrosulindac: 3

(5-fluoro-2-methyl-1-(3,5-dimethoxy-4-hydroxybenzylidene)-3-(N-benzyl)indene)acetamide: 1

2-(1-benzylidene-5-bromo-2-methyl-1H-inden-3-yl)acetic acid

sulindac derivative IND 12

Experts

1.	Giardiello, Francis M: 6 articles (10/2005 - 03/2002)
2.	Rhee, Chang-Hun: 5 articles (09/2008 - 02/2005)
3.	Jin, Hyeon-Ok: 5 articles (09/2008 - 02/2005)
4.	Park, In-Chul: 5 articles (09/2008 - 02/2005)
5.	An, Sungkwan: 5 articles (09/2008 - 02/2005)
6.	Lee, Hyung-Chahn: 5 articles (09/2008 - 02/2005)
7.	Yoo, Doo-Hyun: 5 articles (09/2008 - 02/2005)
8.	Lee, Su-Jae: 5 articles (09/2008 - 02/2005)
9.	Hong, Seok-Il: 5 articles (09/2008 - 02/2005)
10.	Woo, Sang-Hyeok: 5 articles (09/2008 - 02/2005)

Related Diseases

1.	Neoplasms (Cancer) 09/01/1991 - "There was a significantly greater increase in size of the tumors in the control group (56.4 mm for 26 tumors) compared with the rats receiving sulindac (9.3 mm for 14 tumors). " 09/01/2004 - "Combined treatment with sulindac and ursodeoxycholate was more effective than either agent alone for the prevention of tumors throughout the entire intestine. " 08/15/2001 - "In Apc1638(+/-) mice, targeted inactivation of p21 increased intestinal tumor formation in a gene-dose-dependent manner, but inactivation of p21 completely eliminated the ability of sulindac to both inhibit mitotic activity in the duodenal mucosa and to inhibit Apc-initiated tumor formation. " 04/10/2007 - "Our previous studies demonstrated that sulindac, a non-steroidal anti-inflammatory drug, suppressed intestinal tumor formation in mouse, which is linked to the induction of wild-type p53-activated fragment 1 (p21WAF1, or p21). " 12/26/2003 - "Studies with sulindac have indicated that it may also function as an anti-tumor agent by stimulating apoptosis. " Order ALL the reference details at left...
2.	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 01/01/2006 - "BACKGROUND: The aim of the present study was to elucidate the effect of sulindac on uncolectomized familial adenomatous polyposis (FAP). " 01/01/1990 - "The aim of this study was to assess the effectiveness of sulindac therapy for eradication of micropolyps in 8 patients with familial polyposis coli. " 04/01/2007 - "The NSAID (non-steroidal anti-inflammatory drug) sulindac is a potent inhibitor of intestinal carcinogenesis in the C57BL/6J-Apc(Min)/J mouse model and is used to treat humans with FAP (familial adenomatous polyposis). " 01/01/2006 - "The nonsteroidal antiinflammatory drug sulindac displays chemopreventive activity in patients with familial adenomatous polyposis (FAP). " 10/01/2005 - "Sulindac is a nonsteroidal antiinflammatory drug with a chemopreventive effect in patients with familial adenomatous polyposis (FAP). " Order ALL the reference details at left...
3.	Adenoma (Adenomas) 08/01/1995 - "CONCLUSIONS: Low-dose rectal sulindac maintenance therapy is highly effective in achieving complete adenoma reversion without relapse in 87 percent of patients after 33 months. " 01/01/2008 - "Follow-up studies showed positive but variable long-term efficacy for colorectal adenomas, but sulindac appears to lack significant benefit in regressing duodenal adenomas or preventing initial occurrence of adenomas in APC mutation carriers. " 08/18/2005 - "CONCLUSION: Long-term use of sulindac seems to be effective in reducing dysplasia grade and tubulovillous adenoma of retained colorectal adenoma of FAP patients. " 04/04/2002 - "During the course of the study, adenomas developed in 9 of 21 subjects (43 percent) in the sulindac group and 11 of 20 subjects in the placebo group (55 percent) (P=0.54). " 01/01/2002 - "OBJECTIVE: This study was conducted to assess the growth inhibition of colorectal adenoma cells by sulindac and identify the possible mechanisms. " Order ALL the reference details at left...
4.	Polyps 02/20/1996 - "A second study reported that intervention with the NSAID sulindac for 9 months in young patients with FAP resulted in a significant reduction in both polyp number and size in the rectosigmoid colon. " 08/01/2007 - "Participants in the Phase IIb study served as a vanguard for a randomized, placebo-controlled prospective Phase III trial of the combination of DFMO and sulindac with the primary study endpoint the prevention of colon polyps. " 09/01/1995 - "Despite attempts to reduce polyp mass by regular endoscopic polypectomy, daily transfusions of blood products, and a trial of the non-steroidal anti-inflammatory agent sulindac, his condition gradually deteriorated and he died of septicaemia." 05/06/1993 - "Administration of the nonsteroidal antiinflammatory drug sulindac has been followed by regression of polyps in patients with this disorder, but no controlled trial of this drug in patients who have not had surgery has been reported. " 10/01/2005 - "Six patients exhibited polymorphisms in both E158K and E308G loci and were designated as genotype combination 1. The remaining patients were designated as genotype combination 2. Over the course of treatment, patients with genotype combination 1 had a greater reduction in both the size and number of polyps than those with genotype combination 2. These results suggest that combined polymorphic changes in the E158K and E308G alleles may protect against polyposis in patients with FAP treated with sulindac." Order ALL the reference details at left...
5.	Rheumatoid Arthritis 04/25/1979 - "Sulindac appears to be an effective anti-inflammatory analgesic drug for the management of rheumatoid arthritis with a low incidence of side effects." 03/01/1995 - "She received a non-steroidal anti-inflammatory agent (sulindac) because of rheumatoid arthritis. " 06/01/1988 - "The efficacy and safety of sulindac (400 mg vs 600 mg daily) in rheumatoid arthritis. " 01/01/1986 - "The efficacy and safety of the nonsteroidal anti-inflammatory drugs imidazole.2-hydroxybenzoate and sulindac were compared in 30 patients with classical or definite rheumatoid arthritis. " 04/01/1979 - "[A multicenter trial of sulindac in rheumatoid arthritis (author's transl)]" Order ALL the reference details at left...

Related Drugs and Biologics

1.	Tamoxifen
2.	Indomethacin (Indometacin)
3.	Ibuprofen (Motrin)
4.	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)
5.	Aspirin (Acetylsalicylic Acid)
6.	Naproxen (Naprosyn)
7.	Piroxicam (Feldene)
8.	celecoxib (Celebrex)
9.	Diclofenac (SR 38)
10.	Tolmetin (Tolmetin Sodium)

Related Therapies and Procedures

1.	Colectomy
2.	Drug Therapy (Chemotherapy)
3.	Heterologous Transplantation (Xenotransplantation)
4.	Adjuvant Chemotherapy
5.	Chemoprevention

Best Treatments:
Research Summary Report
on Neoplasms

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 20112 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>